ASH 2020 | CARITUDE-1: cilta-cel achieves deep and durable responses in R/R myeloma
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses preliminary results from the phase Ib/II CARTITUDE-1 trial (NCT03548207), investigating the chimeric antigen receptor (CAR) T-cell therapy, ciltacabtagene autoleucel (cilta-cel), in relapsed/refractory (R/R) multiple myeloma. 97 patients with R/R myeloma received cilta-cel in this study, of which 87.6% were triple-refractory to their last line of therapy. The overall response rate was 94.8% with a stringent complete response rate of 55.7%. These results indicate that a single low-dose infusion of cilta-cel leads to early, deep, and durable responses in heavily pretreated multiple myeloma patients. Dr Delforge also discusses toxcities associated with CAR T-cell therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.
